β‐Amyloid Degradation and Alzheimer′s Disease
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Extensive β‐amyloid (A β) deposits in brain parenchyma in the form of senile plaques and in blood vessels in the form of amyloid angiopathy are pathological hallmarks of Alzheimer′s disease (AD). The mechanisms underlying A β deposition remain unclear. Major efforts have focused on A β production, but there is little to suggest that increased production of A β plays a role in A β deposition, except for rare familial forms of AD. Thus, other mechanisms must be involved in the accumulation of A β in AD. Recent data shows that impaired clearance may play an important role in A β accumulation in the pathogenesis of AD. This review focuses on our current knowledge of A β‐degrading enzymes, including neprilysin (NEP), endothelin‐converting enzyme (ECE), insulin‐degrading enzyme (IDE), angiotensin‐converting enzyme (ACE), and the plasmin/uPA/tPA system as they relate to amyloid deposition in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767 · cited 1×
“The major function of ACE is to catalyze the conversion of angiotensin I (AngI) to angiotensin II (AngII), which plays an important role in maintaining blood pressure, body fluid, and sodium homeostasis [118].”
BackgroundPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
4-Hydroxy-2-nonenal: a product and mediator of oxidative stress
Uchida, K. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00014-6 · Cited by 1,164
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Ott, A., Breteler, M. M. B., van Harskamp, F., Claus, J. J., van der Cammen, T. J. M., Grobbee, D. E., & Hofman, A. (1995) · BMJ · doi:10.1136/bmj.310.6985.970 · Cited by 792
Identification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643 · cited 2×
“Recent data from our study showed that NEP decreased in AD brains, but not in pathological aging (PA), a term to describe neurologically normal individuals with high brain amyloid burden (sufficient to diagnose AD with the Khachaturian criteria), but minimal or no neurofibrillary degeneration (Braak neurofibrillary ta…”
BackgroundSelf-citationDeane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392
Cited by
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
“These enzymes are known to maintain Aβ homeostasis in neurons (Wang et al., 2006).”
Molecular Pathogenesis of Alzheimer's Disease: An Update
Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017) · Annals of Neurosciences · doi:10.1159/000464422 · Cited by 418
Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 381
Astrocyte Biomarkers in Alzheimer’s Disease
Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355
Truncated and modified amyloid-beta species
Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt258 · Cited by 341
Ding, M., Shen, Y., Wang, P., Xie, Z., Xu, S., Zhu, Z., Wang, Y., Lyu, Y., Wang, D., Xu, L., et al. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2641-5 · Cited by 276
Self-citationAβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Increased Accumulation of Intraneuronal Amyloid β in HIV-Infected Patients
HNRC, Achim, C. L., Adame, A., Dumaop, W., Everall, I. P., & Masliah, E. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9152-8 · Cited by 205
“Aβ is degraded by proteases such as neprilysin, insulin-degrading enzyme, and endothelin (Eckman and Eckman 2005; Miners et al. 2008; Nalivaeva et al. 2008; Wang et al. 2006).”
BackgroundChami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168
“Amyloid peptides are mainly degraded enzymatically by neprilysin, but also and, likely to a lesser extent, by insulin degrading enzyme (IDE), endothelin-converting enzyme (ECE), angiotensin-converting enzyme (ACE), and plasmin [13].”
BackgroundDrug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Mannix, R. C., Zhang, J., Park, J., Zhang, X., Bilal, K., Walker, K., Tanzi, R. E., Tesco, G., & Whalen, M. J. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.99 · Cited by 62
Campos-Peña, V., Toral-Rios, D., Becerril-Pérez, F., Sánchez-Torres, C., Delgado-Namorado, Y., Torres-Ossorio, E., Franco-Bocanegra, D., & Carvajal, K. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6768 · Cited by 58
Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease
Chiarini, A., Armato, U., Liu, D., & Dal Prà, I. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00134 · Cited by 51
Pinto, M., Pickrell, A. M., Fukui, H., & Moraes, C. T. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.014 · Cited by 47
(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease
Adalier, N., & Parker, H. (2016) · Antioxidants · doi:10.3390/antiox5040040 · Cited by 40
Krishnan, D., Menon, R. N., Mathuranath, P. S., & Gopala, S. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.001 · Cited by 36
Tikhonova, M. A., Amstislavskaya, T. G., Belichenko, V. M., Fedoseeva, L. A., Kovalenko, S. P., Pisareva, E. E., Avdeeva, A. S., Kolosova, N. G., Belyaev, N. D., & Aftanas, L. I. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0412-5 · Cited by 30
Metadata
- Authors
- Wang, D.-S., Dickson, D. W., & Malter, J. S.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 2006
- Issue
- 1
- Pages
- 58406-58406
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2095082499
- Cited by
- 185
- References
- 21
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.